Clinical Efficacy and Safety of Lacosamide as an Adjunctive Treatment in Adults With Refractory Epilepsy
Background: Lacosamide (LCM), a novel AED (antiepileptic drug), was used as an adjunctive treatment in patients with partial-onset seizures or without secondary generalization. However, no meta-analysis was performed to evaluate the efficacy of LCM as an adjunctive treatment in post-marketing clinic...
Guardado en:
Autores principales: | Liyan Hou, Bingjie Peng, Defu Zhang, Jingjing Yang, Ying Wang, Li Tong, Sheng Li, Qingshan Wang, Jie Zhao |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ce9463c5c36944edab144441934baa87 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Poststroke epilepsy: current perspectives on diagnosis and treatment
por: Sarecka-Hujar B, et al.
Publicado: (2018) -
Magnetic Seizure Therapy Compared to Electroconvulsive Therapy for Schizophrenia: A Randomized Controlled Trial
por: Jiangling Jiang, et al.
Publicado: (2021) -
Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy
por: Sunkaraneni S, et al.
Publicado: (2017) -
A Randomized Controlled Trial of Attentional Control Training for Treating Alcohol Use Disorder
por: Angelina Isabella Mellentin, et al.
Publicado: (2021) -
Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Wang N, et al.
Publicado: (2019)